Pomerantz Law Firm Launches Investigation for Investors of Sanara MedTech, Inc. Amid Securities Fraud Claims

Overview of the Investigation

Pomerantz LLP, a notable law firm specializing in securities fraud litigation, has announced that it is looking into claims on behalf of investors in Sanara MedTech, Inc. (NASDAQ: SMTI) as part of its ongoing efforts to uphold the rights of investors. The investigation arises amidst significant concerns regarding potential fraud and unlawful practices involving the company and some of its executives. Investors who may have suffered losses are being encouraged to come forward and provide information.

Recent Developments at Sanara MedTech, Inc.

On November 11, 2025, Sanara made headlines when it declared the discontinuation of its Tissue Health Plus (THP) program. Management stated that this strategic maneuver aimed to refocus resources towards its primary surgical business and enhance overall operational efficiency. This decision, however, sparked concerns among shareholders.

Subsequent to this announcement, on November 12, the company reported its third-quarter financial results, revealing a startling net loss of $31.2 million attributed to operations that were discontinued. This was largely driven by a massive noncash asset impairment charge of $26.5 million tied directly to the closure of the THP program.

Following these announcements, Sanara's stock suffered a considerable setback, plunging by $6.93 per share or 24.7%. This drop caused its share price to close at $21.11, raising red flags among analysts and investors alike.

Legal Implications

Given the severity of the loss and the implications surrounding the THP program's termination, Pomerantz LLP is meticulously assessing whether Sanara, along with its upper management, may have partaken in securities fraud or breached fiduciary duties to its investors. The firm is well-regarded in the realm of corporate litigation, having established a strong reputation over its 85 years of service in protecting the victims of corporate misconduct.

Pomerantz has created pathways for affected investors to join class action litigation should they wish to seek recompense for their losses. Individuals or entities invested in Sanara MedTech are advised to reach out to Danielle Peyton at [email protected] or contact at 646-581-9980, ext. 7980 for further assistance.

About Pomerantz LLP

Pomerantz LLP, headquartered in New York, with offices spanning across Chicago, Los Angeles, London, Paris, and Tel Aviv, is recognized as one of the leading firms in the areas of corporate, securities, and antitrust class action litigation. Founded by the late Abraham L. Pomerantz, known as the father of the class action bar, the firm has pioneered the domain of securities class actions, establishing a legacy of fighting for justice on behalf of aggrieved investors. Over the decades, Pomerantz has recovered substantial damages for class members, continually committing to uphold investor rights when corporate wrongdoing occurs.

Conclusion

The recent troubles faced by Sanara MedTech, Inc. raise significant concerns for investors who have stakes in the company. The ongoing investigation by Pomerantz LLP aims to uncover the truth behind the operational upheaval and potential securities violations. Investors affected by the events surrounding Sanara are encouraged to stay informed and contact the law firm to explore their legal options moving forward.

For more information regarding this investigation and potential actions, visit www.pomlaw.com.

Investors and interested parties can also keep abreast of updates through news segments and legal forums focusing on investors' rights in the corporate sphere.